AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
Story originally reported by CNBC Markets.
View at CNBC Markets →